Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

A Significant Early Detection Of Poor Outcome In Acute Myeloid Leukemia Patients Having a Minimal Residual Disease Using Multiparameter Flow Cytomerty Combined To Mixed Chimerism At Three Months After Allogeneic Hematopoietic Stem Cell Transplantation

Florence Beckerich, MD, Mohamad Sobh, Pharm.M., Stephane Morisset, Stat., Adriana Plesa, MD, Valerie Dubois, MD, Isabelle Mollet, Helene Labussiere, MD, Lila Gilis, MD, Sophie Ducastelle, MD, Oriane Le Borgne, CRA, Jeremy Monfray, CRA, Fiorenza Barraco, MD, Isabelle Tigaud, MD, Xavier Thomas, MD, Franck E. Nicolini, MD, PhD, Mauricette Michallet, MD, PhD

Blood (2013) 122 (21): 4639.

https://doi.org/10.1182/blood.V122.21.4639.4639

Published: 2013

Journal Articles

Cardio-Vascular Events Occurring On Ponatinib In Chronic Phase Chronic Myeloid Leukemia Patients, Preliminary Analysis Of a Multicenter Cohort

Franck E. Nicolini, MD, PhD, Marie-Claude Gagnieu, PharmD, PhD, Mael Heiblig, MD, Emilie Blond, Pharm.D, Laurence Legros, MD, PhD, Yann Guillermin, MD, Stephane Morisset, Stat., Fiorenza Barraco, MD, Madeleine Etienne, CRA, Oriane Le Borgne, CRA, Jeremy Ruby, CRA student, Mohamad Sobh, Pharm.M., Gaelle Richard-Colmant, MD, Celine Fettig, Tech., Mauricette Michallet, MD, PhD, Delphine Rea, MD, PhD

Blood (2013) 122 (21): 4020.

https://doi.org/10.1182/blood.V122.21.4020.4020

Published: 2013

Journal Articles

Impact Of Major Molecular Response On Overall Survival and Its Time Of Achievement On Complete Molecular Response Incidence In Chronic Myeloid Leukemia Patients Treated By Tyrosine Kinase Inhibitors In First Chronic Phase

Mauricette Michallet, MD, PhD, Mohamad Sobh, Pharm.M, Helene Labussiere, MD, Lila Gilis, MD, Fiorenza Barraco, MD, Madeleine Etienne, CRA, Oriane Le Borgne, CRA, Isabelle Tigaud, MD, Sandrine Hayette, PhD, Sophie Ducastelle, MD, Xavier Thomas, MD

Blood (2013) 122 (21): 2721.

https://doi.org/10.1182/blood.V122.21.2721.2721

Published: 2013

Journal Articles

Analysis of Clinical Arterial and Metabolic Parameters in Chronic Phase CML Patients On Nilotinib in a Single Center Cohort

Hélène Labussière-Wallet, MD, Yann Guillermin, MD, Madeleine Etienne, CRA, Anne-Claire Barale, Caroline Serrier, MD, Isabelle Tigaud, MD, Sandrine Hayette, Oriane Le Borgne, CRA, Mohamad Sobh, Pharm.M., Stephane Morisset, Stat., Fiorenza Barraco, MD, Mauricette Michallet, MD, PhD, Franck E. Nicolini, MD, PhD

Blood (2012) 120 (21): 3756.

https://doi.org/10.1182/blood.V120.21.3756.3756

Published: 2012

Journal Articles

MMR and CMR in Chronic Phase Chronic Myeloid Leukemia Patients: Role of Sokal Score and Different Tyrosine Kinase Inhibitors On Time of Their Obtention, Maintenance and Failure-Free Survival

Mauricette Michallet, MD, PhD, Hélène Labussière-Wallet, MD, Mohamad Sobh, Pharm.M., Stéphane Morisset, Stat., Madeleine Etienne, CRA, Marie Y. Detrait, MD, Sophie Ducastelle, MD, Fiorenza Barraco, MD, Xavier Thomas, MD, Oriane Le Borgne, CRA, Isabelle Tigaud, MD, Sandrine Hayette, Franck E. Nicolini, MD, PhD

Blood (2012) 120 (21): 4437.

https://doi.org/10.1182/blood.V120.21.4437.4437

Published: 2012

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

A Significant Early Detection Of Poor Outcome In Acute Myeloid Leukemia Patients Having a Minimal Residual Disease Using Multiparameter Flow Cytomerty Combined To Mixed Chimerism At Three Months After Allogeneic Hematopoietic Stem Cell Transplantation

Cardio-Vascular Events Occurring On Ponatinib In Chronic Phase Chronic Myeloid Leukemia Patients, Preliminary Analysis Of a Multicenter Cohort

Impact Of Major Molecular Response On Overall Survival and Its Time Of Achievement On Complete Molecular Response Incidence In Chronic Myeloid Leukemia Patients Treated By Tyrosine Kinase Inhibitors In First Chronic Phase

Analysis of Clinical Arterial and Metabolic Parameters in Chronic Phase CML Patients On Nilotinib in a Single Center Cohort

MMR and CMR in Chronic Phase Chronic Myeloid Leukemia Patients: Role of Sokal Score and Different Tyrosine Kinase Inhibitors On Time of Their Obtention, Maintenance and Failure-Free Survival

Email alerts

ASH Publications

American Society of Hematology

Update search

A Significant Early Detection Of Poor Outcome In Acute Myeloid Leukemia Patients Having a Minimal Residual Disease Using Multiparameter Flow Cytomerty Combined To Mixed Chimerism At Three Months After Allogeneic Hematopoietic Stem Cell Transplantation

Cardio-Vascular Events Occurring On Ponatinib In Chronic Phase Chronic Myeloid Leukemia Patients, Preliminary Analysis Of a Multicenter Cohort

Impact Of Major Molecular Response On Overall Survival and Its Time Of Achievement On Complete Molecular Response Incidence In Chronic Myeloid Leukemia Patients Treated By Tyrosine Kinase Inhibitors In First Chronic Phase

Analysis of Clinical Arterial and Metabolic Parameters in Chronic Phase CML Patients On Nilotinib in a Single Center Cohort

MMR and CMR in Chronic Phase Chronic Myeloid Leukemia Patients: Role of Sokal Score and Different Tyrosine Kinase Inhibitors On Time of Their Obtention, Maintenance and Failure-Free Survival

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only